论文部分内容阅读
目的糖脂代谢与动脉硬化密切相关,故糖尿病患者较非糖尿病者更易合并脂肪肝及动脉硬化。研究观察2型糖尿病(type 2 diabetes mellitus,T2DM)大鼠在成模后6周和12周时主动脉与肝的病理学变化,以及罗格列酮的干预作用。方法雄性Wistar大鼠80只,随机分为对照组、高脂组、糖尿病组、罗格列酮治疗组,每组20只。制备T2DM大鼠模型,成模后罗格列酮治疗组予罗格列酮灌胃治疗,先后于灌胃治疗6周和12周时处死部分动物,并留取动物肝与主动脉进行HE染色,在光镜下观察各组动物不同组织的病理学。结果第1、6周时,对照组、高脂组、糖尿病组及罗格列酮治疗组大鼠主动脉未见明显病理改变。12周对照组大鼠动脉壁未见明显病理改变;高脂组、糖尿病组和罗格列酮组大鼠主动脉出现不同程度病理改变。对照组大鼠肝细胞6周和12周时均未见明显病理改变;而糖尿病组、高脂组和罗格列酮组在6周和12周时均出现不同程度肝细胞脂肪变性。糖尿病造模成功后予罗格列酮治疗6周时光镜下观察,高脂组和糖尿病组大鼠主动脉形态学改变不明显,但高脂组肝发生病理学变化,糖尿病组和罗格列酮治疗组的肝形态学均已发生病理变化。糖尿病造模成功后予罗格列酮治疗12周时光镜下观察,高脂组、糖尿病大鼠主动脉和肝均发生病理改变。结论罗格列酮治疗组上述病变呈不同程度减轻,考虑作用可能与其改善胰岛素抵抗及糖脂代谢紊乱有关。
Purpose Glyco-lipid metabolism and arteriosclerosis are closely related, so diabetic patients with non-diabetic patients more easily with fatty liver and arteriosclerosis. To study the pathological changes of the aorta and liver in type 2 diabetes mellitus (T2DM) rats at 6 and 12 weeks after injection and the effect of rosiglitazone intervention. Methods Eighty male Wistar rats were randomly divided into control group, hyperlipidemia group, diabetic group and rosiglitazone treatment group, with 20 rats in each group. Preparation of T2DM rat model, rosiglitazone treatment group after intragastric administration of rosiglitazone treatment, successively in the gavage for 6 weeks and 12 weeks when part of the animals were sacrificed and animals were taken to the liver and aorta HE staining The pathology of different tissues in each group was observed under light microscope. Results At week 1 and week 6, no significant pathological changes were found in the aorta of rats in the control group, hyperlipidemia group, diabetic group and rosiglitazone treatment group. There was no obvious pathological changes in the arterial wall of rats in the 12-week control group. The pathological changes of the aorta were observed in the hyperlipidemia, diabetic and rosiglitazone groups. No significant pathological changes were found in the control group at 6 and 12 weeks, while those in the diabetic group, the hyperlipidemic group and the rosiglitazone group showed varying degrees of hepatic steatosis at 6 and 12 weeks. Diabetic model was successfully treated with rosiglitazone for 6 weeks. The morphological changes of aorta in hyperlipidemic and diabetic rats were not obvious, but the histopathological changes of liver in hyperlipidemic rats were observed. In diabetic and rosiglitazone groups, Pathological changes have occurred in the liver morphology of the ketogenic group. Diabetic models were successfully treated with rosiglitazone for 12 weeks. The pathological changes of the aorta and liver were observed in the hyperlipidemic and diabetic rats. Conclusion The above lesions in Rosiglitazone treatment group were alleviated in varying degrees, which may be related to the improvement of insulin resistance and the disturbance of glucose and lipid metabolism.